Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  CANADIAN NATIONAL STOCK EXCHANGE  >  Chemesis International Inc    CSI   CA1635991039

CHEMESIS INTERNATIONAL INC

(CSI)
SummaryQuotesChartsNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Chemesis International Inc :. Reports Fiscal Q3 2019 Financial Statements

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/01/2019 | 08:35am EDT

(GlobeNewswire) - Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the Company or Chemesis), announces unaudited fiscal Q3 Financial Statements for the three months ending March 31, 2019. In this quarter;

the Company reported Revenue of $3,762,139, a 33% increase over the previous quarter, with Gross Profit of $1,113,903.

the Company closed the acquisition of La Finca Interacviva-Arachna Inc. SAS, an integrated cannabis company operating in Colombia with access to over 1,060 acres of outdoor cultivation.

the Company entered into a definitive agreement to manufacture a Proprietary Patent Pending THC Flake.

the Company announced an exclusive partnership with First Medical Cannabis bringing immediate access to 1,000 acres of hemp cultivation in Puerto Rico. Additionally, the Company has the option to expand to an additional 5,000 acres.

SUBSEQUENT EVENTS

the Company announced the closing of CDN $1,975,000 in equity financings.

the Company completed a definitive agreement for Acquisition of an extraction & manufacturing facility in Cathedral City. The acquisition expanded the Company's processing ability to over 500,000 kg of cannabis annually.

the Company announced multi-state expansion into the Central United States, with teams concentrating on establishing operations in Michigan, Wisconsin, Missouri, and Illinois.

the Company announced it has received approval for three new cultivation licenses in Colombia, with the ability to expand to over 100 acres. Additionally, through its non-profit organization, Chemesis believes it will extend its sowing prospects to add an additional 10,000 acres within the next three years.

the Company announced it agreed with the holders of a $5.5 million promissory notes issued in connection with the Companys acquisition of La Finca Interacviva-Arachna Med SAS to settle the full amount by issuing 4,104,476 common shares subject to 24 month leak out and escrow agreement.

Edgar Montero, CEO of Chemesis stated, the Companys operations continue to see increases in revenue quarter over quarter and we anticipate our operations will continue to grow as we see significant demand for the products we manufacture and package. The company's revenues, accounts receivables, and inventory is as strong as ever. Chemesis is also putting forth further resources to expand into the Eastern United States to continue to expand the Companys multi-state operations. The team has created a foundation that we believe will create significant opportunities in 2019.

Chemesis international still has access to $32,625,000 in drawdown equity facilities between New York based Alumina Partners Inc and Global Emerging Markets at the company's discretion.

The unaudited condensed consolidated interim financial Statements and MD&A for the three months ended March 31, 2019 will be filed on SEDAR and available at www.sedar.com.

On Behalf of The Board of DirectorsEdgar MonteroCEO and Director

About Chemesis International Inc.

Chemesis International Inc. is a vertically integrated U.S. Multi-State operator with International operations in Puerto Rico, and Colombia.

The Company focuses on prudent capital allocation to ensure it maintains a first mover advantage as it enters new markets and is committed to differentiate itself by deploying resources in markets with major opportunities. The Company operates a portfolio of brands which cater to a wide community of cannabis consumers, with focus on quality and consistency.

Chemesis has facilities in both Puerto Rico and California, and is in the process of constructing a GMP certified facility in Colombia. Chemesis Puerto Rico operations are licensed to operate 100,000 ft2 of cultivation, and 35,000 ft2 of manufacturing floor space. The Company is positioned to win additional licenses in highly competitive merit-based US states, and will expand its footprint to ensure it maintains a first mover advantage.

Investor Relations:ir@chemesis.com1 (604) 398-3378

Social Media:

Chemesis.facebookChemesis.twitterChemesis.instagramDesertZen.instagramCaliforniaSap.instagramJay&SB.instagram

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Companys business, its product offerings and plans for sales and marketing, including finalizing an acquisition in Colombia. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release

(c) 2019 Al Hilal Publishing and Marketing Group Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CHEMESIS INTERNATIONAL INC
03:06aChemesis International Inc. Announces Addition of Chief Science Officer, Dr. ..
GL
07/15Chemesis International Inc. Announces Partnership with Happy Tea
GL
07/01Chemesis International Inc. Announces $6,000,000 USD Annual Minimum Purchase ..
GL
06/28CHEMESIS INTERNATIONAL INC : . & Rapid Dose Therapeutics Sign Agreement to Bring..
AQ
06/27CHEMESIS INTERNATIONAL : Rapid Dose Therapeutics and Chemesis to Introduce Innov..
AQ
06/27Chemesis International Inc. & Rapid Dose Therapeutics Sign Agreement to Bring..
GL
06/25CHEMESIS INTERNATIONAL INC : . Receives Approval from the State of Michigan to I..
AQ
06/21CHEMESIS INTERNATIONAL INC : . Receives Hemp Licensing in Central United States
AQ
06/20Chemesis International Inc. Receives Hemp Licensing in Central United States
GL
06/14RAPID DOSE THERAPEUTICS : Announces Commercialization of Quickstrip Oral Thin St..
AQ
More news
Chart CHEMESIS INTERNATIONAL INC
Duration : Period :
Chemesis International Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Edgar Montero Chief Executive Officer & Director
Amandeep Parmar President & Director
Eli Dusenbury Chief Financial Officer
Brian G. Thurston Independent Director
Dave McMillan Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CHEMESIS INTERNATIONAL INC66.33%125
CANOPY GROWTH CORP25.16%12 811
AURORA CANNABIS INC34.66%7 286
BEIJING TONGRENTANG CO., LTD.8.33%5 979
CRONOS GROUP INC34.98%5 074
DONG-E-E-JIAO CO LTD--.--%3 752